202 related articles for article (PubMed ID: 17290727)
1. Eptifibatide vs abciximab as adjunctive therapy during primary percutaneous coronary intervention for acute myocardial infarction.
Raveendran G; Ting HH; Best PJ; Holmes DR; Lennon RJ; Singh M; Bell MR; Long KH; Rihal CS
Mayo Clin Proc; 2007 Feb; 82(2):196-202. PubMed ID: 17290727
[TBL] [Abstract][Full Text] [Related]
2. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).
Akerblom A; James SK; Koutouzis M; Lagerqvist B; Stenestrand U; Svennblad B; Oldgren J
J Am Coll Cardiol; 2010 Aug; 56(6):470-5. PubMed ID: 20670756
[TBL] [Abstract][Full Text] [Related]
3. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.
Zeymer U; Margenet A; Haude M; Bode C; Lablanche JM; Heuer H; Schröder R; Kropff S; Bourkaib R; Banik N; Zahn R; Teiger E
J Am Coll Cardiol; 2010 Aug; 56(6):463-9. PubMed ID: 20670755
[TBL] [Abstract][Full Text] [Related]
4. Comparison of abciximab versus eptifibatide during percutaneous coronary intervention in ST-segment elevation myocardial infarction (from the HORIZONS-AMI trial).
Singh HS; Dangas GD; Guagliumi G; Yu J; Witzenbichler B; Kornowski R; Grines C; Gersh B; Dudek D; Mehran R; Stone GW
Am J Cardiol; 2012 Oct; 110(7):940-7. PubMed ID: 22748356
[TBL] [Abstract][Full Text] [Related]
5. Comparison of abciximab and eptifibatide on angiographic and clinical outcomes in rescue percutaneous coronary intervention for failed fibrinolytic therapy.
Bajaj RR; Mohammad A; Hong T; Irfan A; Sharieff W; Bagnall A; Christie JA; Kutryk MJ; Chisholm RJ; Cheema AN
J Invasive Cardiol; 2010 Aug; 22(8):347-52. PubMed ID: 20679668
[TBL] [Abstract][Full Text] [Related]
6. Long-term results following switch from abciximab to eptifibatide during percutaneous coronary intervention.
Koutouzis M; Lagerqvist B; Oldgren J; Akerblom A; Wahlin M; Karlsson T; Albertsson P; Matejka G; Grip L
Clin Cardiol; 2010 Nov; 33(11):686-92. PubMed ID: 21089113
[TBL] [Abstract][Full Text] [Related]
7. Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.
Kimmelstiel C; Phang R; Rehman A; Rand W; Miele R; Rhofiry J; MacIsaac DA; Gouveia W; Denier D; Becker RC
J Thromb Thrombolysis; 2001 May; 11(3):203-9. PubMed ID: 11577258
[TBL] [Abstract][Full Text] [Related]
8. Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention.
Marmur JD; Poludasu S; Lazar J; Cavusoglu E
Catheter Cardiovasc Interv; 2009 Feb; 73(2):214-21. PubMed ID: 19156882
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes comparing eptifibatide and abciximab in ST elevation acute myocardial infarction patients undergoing percutaneous coronary interventions.
Midei MG; Coombs VJ; Lowry DR; Drossner MN; Prewitt KC; Wang JC; Loughrey MB; Gottlieb SO
Cardiology; 2007; 107(3):172-7. PubMed ID: 16940721
[TBL] [Abstract][Full Text] [Related]
10. Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention.
Marmur JD; Poludasu S; Agarwal A; Vladutiu P; Feit A; Lapin R; Cavusoglu E
J Invasive Cardiol; 2006 Nov; 18(11):521-6. PubMed ID: 17090813
[TBL] [Abstract][Full Text] [Related]
11. Switch from abciximab to eptifibatide during percutaneous coronary intervention.
Wahlin M; Albertsson P; Karlsson T; Matejka G; Odell A; Tahmasebiepour F; Wolmeryd C; Grip L
Int J Cardiol; 2009 May; 134(3):393-400. PubMed ID: 18620765
[TBL] [Abstract][Full Text] [Related]
12. The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention.
Gurm HS; Smith DE; Collins JS; Share D; Riba A; Carter AJ; LaLonde T; Kline-Rogers E; O'Donnell M; Changezi H; Zughaib M; Safian R; Moscucci M;
J Am Coll Cardiol; 2008 Feb; 51(5):529-35. PubMed ID: 18237680
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
[TBL] [Abstract][Full Text] [Related]
14. PCI with and without abciximab after upstream eptifibatide use: outcomes in high-risk patients.
Applegate RJ; Grabarczyk MA; Sane DC; Sacrinty MT; Goodin JE; Statonk GS; Baki TT; Gandhi SK; Kutcher MA; Little WC
J Invasive Cardiol; 2006 Dec; 18(12):604-13. PubMed ID: 17197712
[TBL] [Abstract][Full Text] [Related]
15. A longitudinal analysis of outcomes associated with abciximab and eptifibatide in a consecutive series of 3074 percutaneous coronary interventions.
Long KH; Ting HH; McMurtry EK; Lennon RJ; Wood DL; Holmes DR; Raveendran G; Rihal CS
Value Health; 2008; 11(3):462-9. PubMed ID: 18489669
[TBL] [Abstract][Full Text] [Related]
16. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions.
Karvouni E; Katritsis DG; Ioannidis JP
J Am Coll Cardiol; 2003 Jan; 41(1):26-32. PubMed ID: 12570940
[TBL] [Abstract][Full Text] [Related]
17. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
Valgimigli M; Campo G; Percoco G; Bolognese L; Vassanelli C; Colangelo S; de Cesare N; Rodriguez AE; Ferrario M; Moreno R; Piva T; Sheiban I; Pasquetto G; Prati F; Nazzaro MS; Parrinello G; Ferrari R;
JAMA; 2008 Apr; 299(15):1788-99. PubMed ID: 18375998
[TBL] [Abstract][Full Text] [Related]
18. Outcomes and costs of abciximab versus eptifibatide for percutaneous coronary intervention.
Coons JC; Seybert AL; Saul MI; Kirisci L; Kane-Gill SL
Ann Pharmacother; 2005 Oct; 39(10):1621-6. PubMed ID: 16105872
[TBL] [Abstract][Full Text] [Related]
19. Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
McCollam PL; Foster DA; Riesmeyer JS
Am J Health Syst Pharm; 2003 Jun; 60(12):1251-6. PubMed ID: 12845921
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention.
Labinaz M; Ho C; Banerjee S; Martin J; Chen S; Mensinkai S
Can J Cardiol; 2007 Oct; 23(12):963-70. PubMed ID: 17932572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
